Acepodia's off-the-shelf cell therapies get another $100M for oncology trials
California and Taipei biotech Acepodia has lined up another six-figure funding round to take its off-the-shelf cell therapies forward.
Spun out of Nobel laureate Carolyn Bertozzi’s lab and founded in 2017 by ex-Juno EVP Patrick Yang and UC Berkeley cell biologist Sonny Hsiao, the biotech has now raised a total of $259 million thanks to a $100 million Series D disclosed Tuesday morning.
The round follows a $109 million Series C in December 2021, at which point Yang told Endpoints News the startup would monitor the public markets and consider whether to go public in 2022. But as the markets cooled following a pandemic high, the biotech chose to go with another private round, led by Digital Mobile Venture, to bankroll clinical trials of allogeneic cell therapies in non-Hodgkin lymphoma and EGFR-expressing solid tumors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.